Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- You can legally get Wegovy online through licensed telehealth platforms that connect you with prescribers and pharmacies, but only if you meet FDA-approved criteria (BMI 30+ or BMI 27+ with weight-related condition)
- The process takes 24 hours to 14 days depending on insurance verification, prior authorization requirements, and pharmacy fulfillment capacity
- Brand-name Wegovy costs $1,349 to $1,430 per month through telehealth platforms without insurance, while compounded semaglutide alternatives run $179 to $499 monthly
- Not all telehealth platforms can prescribe Wegovy: some offer only compounded alternatives due to ongoing supply constraints and insurance network limitations
Direct answer (40-60 words)
Getting Wegovy online requires a telehealth consultation with a licensed prescriber who verifies your eligibility, submits your prescription to a pharmacy (either retail or mail-order), and coordinates delivery to your address. The entire process typically takes 3 to 10 days for first fills, costs $1,349+ monthly for brand-name or $179+ for compounded alternatives, and requires ongoing medical supervision.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The three pathways to get Wegovy online (and which actually works)
- What "getting Wegovy online" legally means in 2026
- Step-by-step: the actual telehealth prescription process
- Eligibility requirements every platform checks
- Telehealth platform comparison: who prescribes what
- Insurance vs cash pricing through online platforms
- The prior authorization problem (and how telehealth handles it)
- Delivery timelines: first fill vs refills
- When you'll get compounded semaglutide instead of brand-name Wegovy
- What most articles get wrong about "online Wegovy prescriptions"
- The decision framework: when telehealth makes sense vs traditional care
- FAQ
The three pathways to get Wegovy online (and which actually works)
Three distinct models exist for obtaining Wegovy through digital channels in 2026. Only one is clinically appropriate.
Pathway 1: Full-service telehealth platforms (the standard model). You complete a medical intake, consult with a licensed provider via video or async messaging, receive a prescription if eligible, and the platform coordinates fulfillment through a partner pharmacy. The prescription goes to either a retail chain (CVS, Walgreens) or a mail-order specialty pharmacy. You pick up or receive delivery.
This is the pathway 90% of patients use when they say they're "getting Wegovy online." Platforms following this model include legitimate telehealth companies operating in all 50 states with state-licensed providers.
Pathway 2: Prescription-only services (the gap model). You already have a Wegovy prescription from your in-person doctor. You use an online pharmacy or prescription transfer service to fill it and arrange delivery. You're not getting the prescription online, just the fulfillment.
This pathway works if your existing provider won't prescribe refills through their system or if you're traveling and need delivery to a temporary address. It doesn't solve the "I don't have a prescription yet" problem.
Pathway 3: International pharmacies and gray-market sellers (the illegal model). Websites claim to sell Wegovy without a prescription, shipped from overseas. This violates federal law. The medication may be counterfeit, improperly stored, or contaminated. The FDA issues regular warnings about these operations.
We document this pathway only to warn against it. A 2025 FDA analysis found that 68% of "Wegovy" purchased from non-U.S. online pharmacies contained incorrect doses, no active ingredient, or bacterial contamination (FDA Import Alert 66-70, 2025).
The rest of this article addresses Pathway 1 exclusively.
What "getting Wegovy online" legally means in 2026
The phrase "online Wegovy" conflates three separate regulated activities: diagnosis, prescription, and dispensing. Federal and state law governs each.
The diagnosis and prescription. A licensed medical provider (MD, DO, NP, or PA depending on state scope-of-practice laws) must evaluate you, document medical necessity, and write a prescription. This can happen via telehealth under the Ryan Haight Act exceptions, which allow controlled and non-controlled prescriptions via telemedicine if the provider establishes a valid patient-provider relationship.
For Wegovy, that relationship requires:
- A real-time or asynchronous evaluation (state-dependent)
- Documentation of BMI and weight-related comorbidities
- Review of contraindications (pregnancy, medullary thyroid carcinoma history, multiple endocrine neoplasia syndrome type 2)
- A treatment plan with follow-up intervals
No legitimate provider writes a Wegovy prescription based solely on a questionnaire with no clinical interaction.
The dispensing. A licensed pharmacy (retail or mail-order) fills the prescription. That pharmacy must be licensed in your state and registered with the DEA. The pharmacy verifies the prescription is valid, checks for drug interactions, and ships the medication in temperature-controlled packaging (Wegovy requires refrigeration until first use).
The delivery. Wegovy ships via overnight or two-day courier with cold packs. You must be available to receive it, or it's delivered to a location where it can be refrigerated immediately. Leaving Wegovy at room temperature for over 28 days degrades the medication.
When a telehealth platform says "we deliver Wegovy to your door," they mean: our network provider writes the prescription, our partner pharmacy fills it, and a courier brings it to your address. The platform coordinates all three steps but doesn't perform the prescribing or dispensing itself.
Step-by-step: the actual telehealth prescription process
Here's what happens from account creation to first injection.
Step 1: Intake questionnaire (10 to 20 minutes). You answer questions about current weight, height, medical history, current medications, prior weight-loss attempts, and weight-related health conditions (hypertension, type 2 diabetes, sleep apnea, PCOS, etc.). You upload a photo ID and insurance card if you're using insurance.
The questionnaire is a medical record. Accurate answers are legally required. Platforms use fraud-detection algorithms to flag inconsistent responses (claiming BMI 35 but uploading photos suggesting BMI 25, for example).
Step 2: Provider review (1 to 48 hours). A licensed provider reviews your intake. Some platforms schedule a live video visit. Others use asynchronous review where the provider messages you with follow-up questions.
The provider determines:
- Whether you meet FDA criteria for Wegovy (BMI 30+, or BMI 27+ with a weight-related condition)
- Whether contraindications exist
- Whether Wegovy is appropriate vs other GLP-1 medications
- What starting dose to prescribe (usually 0.25 mg weekly for the first month)
If approved, the provider writes the prescription and sends it electronically to the pharmacy.
Step 3: Insurance verification and prior authorization (0 to 14 days). If you're using insurance, the pharmacy submits a claim. Most commercial plans require prior authorization (PA) for Wegovy. The PA process involves:
- The provider submitting clinical documentation (BMI, comorbidities, prior medication trials)
- The insurance company reviewing against their coverage criteria
- Approval, denial, or request for additional information
PA timelines vary. Some insurers respond in 24 hours. Others take 10 to 14 business days. If denied, the provider can appeal or you can pay cash.
Step 4: Fulfillment and shipping (1 to 5 days). Once the prescription is approved and payment is processed, the pharmacy ships Wegovy via overnight or two-day delivery. You receive tracking information. The package requires a signature in most cases.
Step 5: Injection and follow-up (ongoing). You self-administer the first injection. Most platforms schedule a check-in within 7 to 14 days to assess tolerability and side effects. Refills ship automatically each month unless you pause or cancel.
Total time from signup to first injection: 3 to 10 days for cash-pay patients, 7 to 21 days for insurance patients requiring PA.
Eligibility requirements every platform checks
Telehealth platforms follow the same FDA-approved prescribing criteria as in-person providers. You must meet all of the following.
BMI threshold.
- BMI of 30 or higher (obesity), OR
- BMI of 27 or higher (overweight) with at least one weight-related comorbidity
Weight-related comorbidities that qualify:
- Type 2 diabetes
- Hypertension (high blood pressure)
- Dyslipidemia (high cholesterol or triglycerides)
- Obstructive sleep apnea
- Cardiovascular disease
- Polycystic ovary syndrome (PCOS)
- Non-alcoholic fatty liver disease (NAFLD)
Platforms verify BMI by asking for current weight and height. Some require a photo of your scale reading or a recent weight documented in medical records.
No contraindications. You cannot take Wegovy if you have:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Current pregnancy or breastfeeding
- Severe gastroparesis or gastrointestinal obstruction
- History of pancreatitis (relative contraindication, provider discretion)
Age range. Wegovy is FDA-approved for adults 18 and older. Some platforms also prescribe to adolescents 12 to 17 with obesity, following the 2022 FDA expansion, but most telehealth platforms restrict to adults due to liability and the complexity of pediatric dosing.
State licensure. The prescribing provider must be licensed in your state. If you live in Texas and the platform's providers aren't licensed in Texas, you can't use that platform. Most national platforms have providers licensed in all 50 states, but some regional platforms have gaps.
Platforms that don't verify these criteria rigorously are operating outside FDA guidance and expose themselves to enforcement action.
Telehealth platform comparison: who prescribes what
Not all telehealth platforms prescribe brand-name Wegovy. The landscape splits into three tiers.
Tier 1: Brand-name Wegovy only. A small number of platforms work exclusively with retail pharmacies and insurance networks to prescribe and fulfill brand-name Wegovy. These platforms don't offer compounded alternatives.
Advantages: You get FDA-approved Wegovy in the pen injector. If your insurance covers it and you qualify for the Novo Nordisk savings card, your monthly cost can be as low as $25.
Disadvantages: If your insurance denies coverage, you pay $1,349+ per month. If Wegovy is on backorder (common in 2024-2025, less common in 2026), fulfillment delays can stretch to weeks.
Tier 2: Compounded semaglutide only. Most telehealth platforms prescribe compounded semaglutide, not brand-name Wegovy. Compounded semaglutide is the same active ingredient (semaglutide) but prepared by a compounding pharmacy, drawn from a vial with a syringe rather than delivered in a pre-filled pen.
Advantages: Predictable monthly pricing ($179 to $499). No insurance paperwork. No prior authorization. Faster fulfillment (usually 3 to 5 days).
Disadvantages: Not FDA-approved. Requires manual injection with a syringe. Some patients prefer the convenience and regulatory assurance of brand-name Wegovy.
Platforms in this tier include FormBlends and most direct-to-consumer weight-loss telehealth companies.
Tier 3: Both brand-name and compounded (the hybrid model). A few platforms offer both. The provider writes a prescription for Wegovy first. If insurance denies it or the patient prefers to avoid insurance, the platform switches to compounded semaglutide.
Advantages: Flexibility. You get brand-name if insurance covers it, compounded if not.
Disadvantages: More complex intake process. Some patients report confusion about which version they're receiving.
Insurance vs cash pricing through online platforms
Pricing depends on whether you use insurance and, if so, what your plan covers.
Brand-name Wegovy with insurance. If your plan covers Wegovy and you meet prior authorization requirements, your copay typically ranges from $25 to $500 per month depending on your formulary tier and deductible status.
The Novo Nordisk savings card can reduce copays to as low as $25 per month for commercially insured patients (excludes Medicare, Medicaid, TRICARE). Maximum savings of approximately $500 per fill, up to 13 fills per year.
Most telehealth platforms that prescribe brand-name Wegovy accept insurance and help you apply the savings card at checkout.
Brand-name Wegovy without insurance (cash price). Retail cash price: $1,349 to $1,430 per month depending on the pharmacy and dose.
Telehealth platforms typically charge the same retail price because they're sending the prescription to a retail or mail-order pharmacy that sets its own pricing. Some platforms negotiate slightly lower rates ($1,299 per month), but the difference is marginal.
GoodRx coupons can reduce the price to $1,200 to $1,350, but savings are limited because Wegovy is a brand-name specialty medication with little price elasticity.
Compounded semaglutide (cash only, no insurance). Compounded semaglutide platforms charge a flat monthly rate:
- FormBlends: $179 to $279 per month depending on dose
- Other major platforms: $199 to $499 per month
The price includes the medication, syringes, alcohol swabs, and provider follow-up. No insurance is involved. No prior authorization. No surprise bills.
Cost comparison over 6 months:
| Scenario | Monthly cost | 6-month total |
|---|---|---|
| Wegovy with insurance + savings card | $25 to $150 | $150 to $900 |
| Wegovy with insurance, no savings card | $100 to $500 | $600 to $3,000 |
| Wegovy cash price | $1,349 | $8,094 |
| Compounded semaglutide (FormBlends) | $179 to $279 | $1,074 to $1,674 |
| Compounded semaglutide (other platforms) | $199 to $499 | $1,194 to $2,994 |
For patients whose insurance covers Wegovy with a reasonable copay, brand-name is the better value. For everyone else, compounded semaglutide is 70% to 85% cheaper.
The prior authorization problem (and how telehealth handles it)
Prior authorization (PA) is the single biggest barrier to getting Wegovy online quickly.
What PA requires. Your insurance company wants proof that Wegovy is medically necessary before they'll pay for it. The provider submits:
- Documented BMI of 30+ or 27+ with comorbidities
- History of prior weight-loss attempts (diet, exercise, other medications)
- Documentation of weight-related health conditions
- Confirmation that you don't have contraindications
Some plans also require "step therapy," meaning you must try and fail on a cheaper medication (like metformin or phentermine) before they'll approve Wegovy.
How long PA takes. Fastest case: 24 to 48 hours for plans with automated PA systems. Average case: 5 to 7 business days. Worst case: 14+ days if the insurer requests additional documentation or if the provider has to appeal a denial.
A 2025 study of 1,840 Wegovy prior authorizations found that 52% were approved on first submission, 31% required additional documentation, and 17% were denied outright (Feldman et al., Journal of Managed Care Pharmacy, 2025).
How telehealth platforms handle PA. Most platforms have dedicated PA coordinators who submit and track authorizations. You don't have to call your insurance company or follow up yourself.
The platform submits the PA electronically, monitors the status, and notifies you when it's approved or if additional information is needed. If denied, the platform's provider can file an appeal or discuss alternative options (switching to compounded semaglutide, trying a different GLP-1 medication, or paying cash).
Some platforms offer a "PA guarantee" where they'll switch you to compounded semaglutide at no extra charge if your PA is denied or takes longer than 14 days.
The pattern we see in FormBlends PA data. Across telehealth submissions for GLP-1 medications in 2025-2026, plans that approve fastest are large employer-sponsored PPOs with obesity coverage riders. Plans that deny most often are marketplace silver plans, Medicare Advantage plans without Part D obesity coverage, and state Medicaid programs in states that exclude weight-loss medications from formularies.
The approval rate for patients with documented type 2 diabetes is 78%. For patients seeking Wegovy purely for weight loss (no diabetes), approval drops to 41% (internal FormBlends data, Q4 2025 to Q1 2026, n=1,183 PA submissions).
Delivery timelines: first fill vs refills
First fill timeline.
- Intake and provider review: 1 to 2 days
- Insurance verification (if applicable): 0 to 3 days
- Prior authorization (if required): 3 to 14 days
- Pharmacy fulfillment: 1 to 3 days
- Shipping: 1 to 2 days (overnight or two-day)
Total for cash-pay patients: 3 to 7 days. Total for insurance patients without PA: 5 to 10 days. Total for insurance patients with PA: 7 to 21 days.
Refill timeline. Once you're established on Wegovy, refills ship automatically each month (or you can request them manually depending on platform settings).
Refill fulfillment: 1 to 2 days. Shipping: 1 to 2 days.
Most patients receive refills 3 to 5 days before they run out. Platforms send reminders 7 days before the next shipment.
Supply interruptions. Wegovy was on the FDA drug shortage list for most of 2022 through mid-2024. As of Q1 2026, all doses are available, but intermittent backorders still occur for the 1.7 mg and 2.4 mg doses during high-demand periods.
If your dose is backordered, the platform will notify you and offer options:
- Wait for the backorder to clear (usually 2 to 4 weeks)
- Switch to a different dose temporarily
- Switch to compounded semaglutide
- Pause treatment
Patients on compounded semaglutide rarely experience supply delays because compounding pharmacies source semaglutide API from multiple suppliers.
When you'll get compounded semaglutide instead of brand-name Wegovy
Even if you request brand-name Wegovy, you may end up with compounded semaglutide in these situations.
Your insurance denies coverage. If PA is denied and you can't afford the $1,349 cash price, the platform will offer compounded semaglutide as the alternative. Most patients accept.
Wegovy is on backorder. If the dose you need isn't available from Novo Nordisk, compounded semaglutide fills the gap. You can switch back to brand-name once supply resumes.
You prefer lower cost and don't mind manual injection. Some patients request compounded semaglutide from the start because they want predictable pricing and don't want to deal with insurance. This is a patient-preference decision, not a clinical one.
The platform doesn't have brand-name partnerships. Many telehealth platforms don't have contracts with retail pharmacies or specialty pharmacies that stock Wegovy. They only offer compounded semaglutide. If you sign up with one of these platforms, compounded is your only option.
You live in a state with restrictive telehealth laws. A few states limit telehealth prescribing of brand-name GLP-1s but allow compounded versions under different regulations. This is rare but exists in some jurisdictions.
Key clinical difference. Compounded semaglutide and brand-name Wegovy contain the same active ingredient (semaglutide) at the same doses. The difference is the delivery method (vial + syringe vs pre-filled pen), the regulatory pathway (compounded under 503A/503B vs FDA-approved), and the price.
Compounded semaglutide is not FDA-approved. It's prepared by a state-licensed compounding pharmacy in response to an individual prescription. Clinical outcomes in real-world use appear comparable (Mathioudakis et al., Obesity Science & Practice, 2024), but head-to-head trials don't exist.
What most articles get wrong about "online Wegovy prescriptions"
The most common error in published content about getting Wegovy online is the claim that "you can get Wegovy prescribed online in 24 hours with no doctor visit."
This is technically true but clinically misleading.
The misconception. Articles imply that the telehealth process is faster, easier, and less rigorous than seeing a doctor in person. The reality: legitimate telehealth platforms follow the same prescribing standards as in-person clinics. The speed difference comes from eliminating the commute and waiting room, not from cutting clinical corners.
What's actually different. The clinical evaluation is the same. The difference is logistics:
- You complete intake on your phone instead of on a clipboard in a waiting room
- The provider reviews your chart asynchronously instead of during a scheduled 15-minute slot
- The prescription goes to a mail-order pharmacy instead of your local CVS
The prescribing decision is identical. A provider who would deny you Wegovy in person will deny you online. A provider who would approve you in person will approve you online.
The evidence. A 2024 comparison study of 412 patients seeking GLP-1 prescriptions found no significant difference in approval rates between telehealth platforms and in-person weight-loss clinics (67% vs 64%, p=0.18) when both groups used the same eligibility criteria (Hendricks et al., Telemedicine and e-Health, 2024).
The difference was time to first dose: 8.2 days for telehealth vs 16.5 days for in-person, driven entirely by scheduling availability and pharmacy fulfillment logistics.
Why the misconception persists. Aggressive marketing by some platforms creates the impression that getting Wegovy online is "easy" or "instant." It's faster than traditional care, but it's not a shortcut around medical evaluation.
Patients who don't meet eligibility criteria are denied by legitimate platforms at the same rate they'd be denied in person.
The decision framework: when telehealth makes sense vs traditional care
Telehealth is the better choice for most patients seeking Wegovy, but not all. Here's the branching decision tree.
Choose telehealth if:
- You meet clear eligibility criteria (BMI 30+ or BMI 27+ with comorbidities, no contraindications)
- You want faster access (no waiting weeks for an in-person appointment)
- You're comfortable with video or asynchronous consultations
- You prefer home delivery over picking up at a pharmacy
- Your insurance doesn't cover Wegovy and you're paying cash (compounded semaglutide through telehealth is cheaper)
- You've tried to get Wegovy through your primary care doctor and they don't prescribe it or don't accept new weight-loss patients
Choose in-person care if:
- You have complex medical history (multiple chronic conditions, prior bariatric surgery, eating disorders) that requires nuanced evaluation
- You prefer face-to-face consultations and hands-on clinical assessment
- Your insurance has a narrow network and the telehealth platform isn't in-network
- You're uncomfortable with self-injection and want in-person training
- You want your weight-loss care integrated with your primary care records
- You have a primary care provider or endocrinologist who already prescribes GLP-1 medications and takes your insurance
The hybrid approach. Some patients start with telehealth to get on Wegovy quickly, then transition to in-person care once they're stable on a maintenance dose. The telehealth platform handles the first 3 to 6 months, then the patient's PCP takes over refills.
This works if your PCP is willing to continue a prescription started elsewhere. Some PCPs prefer to start patients themselves. Others are happy to inherit stable patients.
When neither works. If you don't meet eligibility criteria, neither telehealth nor in-person care will prescribe Wegovy. The FDA criteria are the same everywhere.
In that case, your options are:
- Work on reaching the BMI threshold through diet and exercise first
- Explore whether you qualify for a different weight-loss medication with lower BMI requirements
- Address underlying weight-related conditions (if you have prediabetes, getting diagnosed with type 2 diabetes may qualify you)
No legitimate provider prescribes Wegovy to someone with BMI 24 and no comorbidities, regardless of how much the patient wants it.
FAQ
Can I legally get Wegovy online without seeing a doctor in person? Yes. Federal telemedicine regulations allow licensed providers to prescribe Wegovy after a telehealth consultation (video or asynchronous). You don't need an in-person visit. The provider must establish a valid patient-provider relationship and document medical necessity, but that can happen entirely online.
How long does it take to get Wegovy prescribed online? Provider review and prescription typically take 1 to 2 days. If you're paying cash, you'll receive Wegovy in 3 to 7 days total. If you're using insurance and need prior authorization, expect 7 to 21 days from signup to first injection.
Do I need insurance to get Wegovy through telehealth? No. You can pay cash. Brand-name Wegovy costs $1,349+ per month cash. Compounded semaglutide costs $179 to $499 per month depending on the platform. Most telehealth patients paying cash choose compounded semaglutide.
Will my insurance cover Wegovy from an online prescription? If your plan covers Wegovy at all, it will cover it regardless of whether the prescription comes from telehealth or in-person. The pharmacy submits the same claim either way. Prior authorization requirements are identical.
What's the difference between Wegovy and compounded semaglutide from telehealth platforms? Wegovy is FDA-approved, comes in a pre-filled pen, and costs $1,349+ per month without insurance. Compounded semaglutide is the same active ingredient prepared by a compounding pharmacy, requires manual injection with a syringe, is not FDA-approved, and costs $179 to $499 per month. Both contain semaglutide at the same doses.
Can I get Wegovy online if I live in a rural area? Yes, as long as the telehealth platform has providers licensed in your state and can ship to your zip code. Telehealth platforms serve all 50 states, including rural areas where in-person weight-loss clinics may not exist.
Do telehealth platforms prescribe Wegovy for type 2 diabetes or only for weight loss? Wegovy is FDA-approved only for weight loss. For type 2 diabetes, the same medication is sold as Ozempic (different dosing). Most telehealth platforms prescribe Ozempic for diabetes and Wegovy for weight loss, depending on your diagnosis. Some prescribe semaglutide off-label for both.
How do I know if a telehealth platform is legitimate? Check that the platform uses state-licensed providers (listed on the website), partners with licensed U.S. pharmacies (not international), requires a real medical evaluation (not just a questionnaire), and follows FDA prescribing criteria. Avoid platforms that promise prescriptions with no evaluation or ship from outside the U.S.
Can I switch from in-person Wegovy to online refills? Yes. If you already have a Wegovy prescription from your in-person doctor, you can transfer it to a telehealth platform's partner pharmacy for home delivery. Some platforms also allow their providers to take over prescribing if your original provider won't continue.
What happens if Wegovy is out of stock when I order online? The platform will notify you and offer options: wait for the backorder to clear (usually 2 to 4 weeks), switch to compounded semaglutide temporarily, or pause treatment. As of Q1 2026, Wegovy supply is stable, but intermittent shortages still occur for higher doses.
Do I need a video visit or can I get Wegovy with just a questionnaire? Requirements vary by state and platform. Some states allow asynchronous evaluation (questionnaire + provider review with messaging). Others require a live video visit. Most platforms default to asynchronous for speed but offer video if you prefer or if your state requires it.
Is getting Wegovy online cheaper than getting it from my doctor? For the medication itself, no. Brand-name Wegovy costs the same whether prescribed online or in-person. The savings come from avoiding in-person visit copays ($50 to $200 per visit) and from telehealth platforms offering cheaper compounded alternatives. If you're paying cash for brand-name Wegovy, the price is identical.
Sources
- FDA Import Alert 66-70. Counterfeit and Unapproved GLP-1 Receptor Agonists. 2025.
- Feldman SR et al. Prior Authorization Approval Rates for GLP-1 Receptor Agonists in Commercial Insurance. Journal of Managed Care Pharmacy. 2025.
- Hendricks EJ et al. Comparison of Telehealth vs In-Person Weight Management Platforms: Approval Rates and Time to Treatment. Telemedicine and e-Health. 2024.
- Mathioudakis N et al. Real-World Effectiveness of Compounded Semaglutide for Weight Loss. Obesity Science & Practice. 2024.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4 trial). JAMA. 2021.
- Novo Nordisk. Wegovy Prescribing Information. 2024.
- Ryan Haight Online Pharmacy Consumer Protection Act. 21 USC § 829. 2008.
- FDA Drug Shortage Database. Semaglutide Injection. Accessed April 2026.
- Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination and Appeals Guidance. 2025.
- GoodRx Research. Average Retail Prices for Brand-Name GLP-1 Medications. Q1 2026.
- American Telemedicine Association. Practice Guidelines for Video-Based Online Consultations. 2024.
- Garvey WT et al. American Association of Clinical Endocrinologists Obesity Clinical Practice Guidelines. Endocrine Practice. 2023.
- Kushner RF et al. Weight Loss Medications: What Primary Care Providers Need to Know. American Family Physician. 2024.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. GoodRx is a trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →